St Luke's Hospice Services 101 St Lukes Center Drive, Chesterfield, MO, 63017 | |
(314) 205-6707 |
News Archive
Axolotl Corp., the nationwide leader in health information exchange services and solutions, today introduced Elysium Discover, the industry's first comprehensive suite of reporting and analytic tools designed specifically for Health Information Exchanges.
The scientific evidence is clear. As a result of extraordinary advances in biomedical research, we now have the tools we need to end the HIV epidemic in the United States. Or do we?
Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.
› Verified 6 days ago
Name | St Luke's Hospice Services |
---|---|
Location | 101 St Lukes Center Drive, Chesterfield, Missouri |
Hospice ID | 261627 |
Category | Part of a hospital |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
SSA county code | 940 |
News Archive
Axolotl Corp., the nationwide leader in health information exchange services and solutions, today introduced Elysium Discover, the industry's first comprehensive suite of reporting and analytic tools designed specifically for Health Information Exchanges.
The scientific evidence is clear. As a result of extraordinary advances in biomedical research, we now have the tools we need to end the HIV epidemic in the United States. Or do we?
Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.
› Verified 6 days ago
NPI Number | 1851624381 |
Organization Name | St. Lukes Episcopal Presbyterian Hospital |
Address | 111 South Woods Mill Road Chesterfield, Missouri, 63017 |
Phone Number | (314)205-6707 |
News Archive
Axolotl Corp., the nationwide leader in health information exchange services and solutions, today introduced Elysium Discover, the industry's first comprehensive suite of reporting and analytic tools designed specifically for Health Information Exchanges.
The scientific evidence is clear. As a result of extraordinary advances in biomedical research, we now have the tools we need to end the HIV epidemic in the United States. Or do we?
Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.
› Verified 6 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 99.3 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 98.4 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 80.2 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 99.7 | 97.3 |
Patients who got timely treatment for shortness of breath | 97.9 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 93.8 | 93.3 |
News Archive
Axolotl Corp., the nationwide leader in health information exchange services and solutions, today introduced Elysium Discover, the industry's first comprehensive suite of reporting and analytic tools designed specifically for Health Information Exchanges.
The scientific evidence is clear. As a result of extraordinary advances in biomedical research, we now have the tools we need to end the HIV epidemic in the United States. Or do we?
Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.
› Verified 6 days ago
Home Health Aides | 2 |
Counselors | 1.9 |
Homemakers | 1 |
Medical Social Workers | 2 |
Physicians | 0.5 |
Registered Nurses | 8.4 |
Other Personnel | 5 |
Total Employees | 20.8 |
---|
News Archive
Axolotl Corp., the nationwide leader in health information exchange services and solutions, today introduced Elysium Discover, the industry's first comprehensive suite of reporting and analytic tools designed specifically for Health Information Exchanges.
The scientific evidence is clear. As a result of extraordinary advances in biomedical research, we now have the tools we need to end the HIV epidemic in the United States. Or do we?
Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.
› Verified 6 days ago
Others | 36 |
Total Volunteers | 36 |
---|
News Archive
Axolotl Corp., the nationwide leader in health information exchange services and solutions, today introduced Elysium Discover, the industry's first comprehensive suite of reporting and analytic tools designed specifically for Health Information Exchanges.
The scientific evidence is clear. As a result of extraordinary advances in biomedical research, we now have the tools we need to end the HIV epidemic in the United States. Or do we?
Boehringer Ingelheim Pharmaceuticals, Inc. and the Duke Clinical Research Institute (DCRI) announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.
› Verified 6 days ago
Pathways Hospice And Palliative Care Location: 14805 North Outer 40 Road, Suite 160, Chesterfield, Missouri, 63017 Phone: (314) 205-6707 |
St Luke's Hospice Services Location: 101 St Lukes Center Drive, Chesterfield, Missouri, 63017 Phone: (314) 205-6707 |
Crossroads Hospice Of Saint Louis, Llc Location: 15450 South Outer Forty Drive, Suite 100, Chesterfield, Missouri, 63017 Phone: (314) 205-6707 |